Alnylam Rallies 62% in a Year: Can the Stock Maintain This Momentum?

Core Viewpoint - Alnylam Pharmaceuticals is focused on developing RNAi-based therapeutics, with a strong pipeline and increasing sales of marketed drugs driving significant stock price growth [1][2]. Marketed Drug Portfolio - Alnylam's lead drug, Amvuttra, generated sales of $970.5 million in 2024, reflecting a 74$422.9 million in 2024, up 29% year-over-year [5]. - Alnylam collaborates with Novartis to market Leqvio, which is approved in over 100 countries and is undergoing late-stage studies for further label expansion [6]. Pipeline Development Programs - Alnylam is seeking label expansion for Amvuttra to treat ATTR amyloidosis with cardiomyopathy, with a decision expected from the FDA on March 23, 2025 [7][8]. - The company is developing cemdisiran in partnership with Regeneron for various indications, with exclusive rights granted to Regeneron for certain developments [9]. - Alnylam has regained full rights to mivelsiran for Alzheimer's disease and expects to report interim data in the second half of 2025 [10]. - Collaboration with Roche on zilebesiran has shown promising results in phase II studies, with further studies planned for 2025 [11][12]. Growth Potential - Successful development and commercialization of the pipeline candidates are expected to significantly boost Alnylam's growth [13].